Log In
Print
BCIQ
Print
Print this Print this
 

VB-201

  Manage Alerts
Collapse Summary General Information
Company VBL Therapeutics Ltd.
DescriptionToll-like receptor 2 (TLR2) and TLR4 antagonist that inhibits production of proinflammatory cytokines IL-12 and IL-23
Molecular Target Toll-like receptor 2 (TLR2) ; Toll-like receptor 4 (TLR4)
Mechanism of ActionInterleukin-12 (IL-12) inhibitor; Interleukin-23 (IL-23) inhibitor
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase II
Standard IndicationAtherosclerosis
Indication DetailsTreat atherosclerosis
Regulatory Designation

Partner


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today